Form 4: Director Jerrold Grossman Increases Stake in ADMA Biologics

Director Jerrold B. Grossman acquired 12,500 shares of ADMA Biologics common stock in an open market transaction.

Summary

• Director Jerrold B. Grossman purchased 12,500 shares of ADMA Biologics common stock at a price of $8.01 per share.
• The transaction occurred on May 11, 2026.
• Following this acquisition, the director's direct beneficial ownership increased to 501,384 shares.
• The director maintains additional indirect holdings through various entities and family accounts totaling 92,707 shares.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as director-level open market purchases typically indicate confidence in the company's long-term prospects.

Positives

• Insider confidence is demonstrated by the director's open market purchase of company stock.
• The purchase price of $8.01 reflects a commitment to the company's current valuation.

Negatives

• None identified in this filing.

Risks

• The vesting of 10,690 RSUs is contingent upon the director's continued service through February 9, 2027.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that insider buying is generally viewed as a positive signal by the market, suggesting that those with the most intimate knowledge of the company's pipeline and financial health believe the stock is undervalued.

Comparison to Industry Standards

• Insider purchases are a standard indicator of management alignment with shareholder interests in the biotechnology sector.
• The scale of the purchase is consistent with typical director-level equity accumulation patterns.

Related Party Transactions

• The director maintains indirect ownership through Brookwood LLC, the Jerrold Grossman 2019 Irrevocable Trust, Genesis Foundation Inc., and his spouse.

Stakeholder Impact

• Shareholders may interpret this purchase as a vote of confidence in the company's strategic direction.

Next Steps

• Vesting of 10,690 RSUs scheduled for February 9, 2027.

Key Dates

Keywords

ADMA Biologics, Insider Trading, Form 4, Director Purchase, Biotech